Maurizio Chiriva-Internati, PhD

Maurizio Chiriva-Internati, PhD, D BSc, is Kiromic’s Chief Executive Officer and Chief Scientific Officer. For the past 20 years, Dr. Chiriva-Internati has investigated tumor antigens as therapeutic and diagnostic tools. His research has led to the identification of novel cancer testis antigens for the development of immunotherapeutic strategies against solid and non-solid tumors. Dr. Chiriva-Internati’s research is focused on developing new therapies for a variety of tumors, including multiple myeloma, acute myeloid leukemia, ovarian, lung, prostate, melanoma, and breast cancer. He is the author of 149 peer-reviewed publications, and is a journal reviewer for The Lancet Infectious Diseases, Cancer Research, The Journal of Immunology, International Reviews of Immunology, and Nature Reviews Clinical Oncology.